<DOC>
	<DOCNO>NCT02571855</DOCNO>
	<brief_summary>The purpose study evaluate tolerability , safety , pharmacokinetics ( PK , amount drug time body ) pharmacodynamics ( PD , effect body ) ACT-541468 follow multiple ascend dos healthy adult follow single ascend dos healthy elderly subject administer morning . The safety , PK PD ACT-541468 also assess repeat even administration select dose healthy adult elderly .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) ACT-541468 Healthy Young Adults Elderly Subjects</brief_title>
	<detailed_description>In first-in-man study , single dose ACT-541468 administer healthy young adult well tolerate dose level 200 mg ( inclusive ) yield result compatible possible sleep facilitating effect ACT-541468 . So present study aim investigate effect ACT-541468 multiple ascend dos healthy young subject well single ascend dos elderly subject ( morning administration ) . The effect repeat administration select dose administer even healthy adult elderly , also investigate .</detailed_description>
	<criteria>Signed informed consent . Adults age 18 45 year ( inclusive ) Part A ; elderly age 65 80 year ( inclusive ) Part B ; adult 18 45 year elderly 65 80 year ( inclusive ) Part C. Regular sleep pattern least 6 hour nocturnal sleep . Young females must negative pregnancy test screen predose Day 1 use reliable method contraception Body mass index ( BMI ) 18.0 30.0 kg/m2 ( inclusive ) screening . Systolic blood pressure ( SBP ) , diastolic blood pressure ( DBP ) pulse rate ( PR ) 100145 mmHg , 5090 mmHg 4590 bpm ( inclusive ) young adult , respectively ; SBP , DBP PR 100160 mmHg , 5095 mmHg 45100 bpm ( inclusive ) elderly , respectively . Healthy basis physical examination , electrocardiogram laboratory test . Principal exclusion criterion common young adult elderly : Pregnant lactate woman . Any contraindication study drug . History presence disease condition treatment , may put subject risk participation study may interfere absorption , distribution , metabolism excretion study drug . History narcolepsy cataplexy modify Swiss narcolepsy scale total score &lt; 0 screening . Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol . Exclusion criterion young adult : Treatment prescribed medication overthecounter medication within 2 week prior study drug administration . Exclusion criteria elderly : Previous chronic treatment medication give stable dos and/or stable regimen within 2 month prior screen . Previous treatment CNSactive drug within 2 month prior screen . Treatment inhibitor CYP3A4 ( e.g. , azole derivative , ritonavir , clarithromycin ) 2 week prior screen visit EOS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>insomnia</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Healthy</keyword>
</DOC>